McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
Pre-Market: $481.53 -0.74 (-0.15%) 9:12 AM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
Pre-Market: $481.53 -0.74 (-0.15%) 9:12 AM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Here's Why McKesson (MCK) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.
McKesson (MCK) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
McKesson (MCK) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -2.52% and 3%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will These 5 Medical Device Stocks Beat This Earnings Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
McKesson (MCK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $530.27 in the latest trading session, marking a -0.16% move from the prior day.
Seeking Clues to McKesson (MCK) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for McKesson (MCK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Becton Dickinson (BDX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 7.09% and 0.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Earnings Preview: McKesson (MCK) Q4 Earnings Expected to Decline
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the closing of the recent trading day, McKesson (MCK) stood at $543.30, denoting a +0.62% change from the preceding trading day.
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
by Zacks Equity Research
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Apple, NVIDIA, Eli Lilly, American Tower and McKesson
by Zacks Equity Research
Apple, NVIDIA, Eli Lilly, American Tower and McKesson are included in this Analyst Blog.
Top Stock Reports for Apple, NVIDIA & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and Eli Lilly and Company (LLY).
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Here's Why You Should Hold McKesson (MCK) in Your Portfolio
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
UnitedHealth's (UNH) Payment System Disrupted by Cyberattack
by Zacks Equity Research
A cyberattack on UnitedHealth's (UNH) payment management subsidiary, Change Healthcare, last month continues to impact healthcare services, especially cancer treatments, as payment processing remains disrupted.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.